Immune Processes Linked to Multiple Sclerosis Genetics
By LabMedica International staff writers Posted on 17 Oct 2019 |
Image: A multiple sclerosis chip (MS chip) was designed using the Illumina iSelect platform (Photo courtesy of Illumina).
Multiple sclerosis (MS) is an autoimmune inflammatory degenerative disease of the central nervous system that often starts in young adulthood and affects 2.3 million individuals worldwide. While prior genetic studies have implicated the adaptive immune system in the disease, in particular T cells, much of the genetic architecture of MS has remained unknown.
The role of the adaptive arm of the immune system, particularly its CD4+ T cell component, has become clearer, with multiple different T cell subsets being implicated. Although the T cell component plays an important role, functional and epigenomic annotation studies have begun to suggest that other elements of the immune system may be involved as well.
Scientists involved with the International Multiple Sclerosis Genetics Consortium (Boston, MA, USA) analyzed genotyping data from a total of more than 47,000 MS patients and more than 68,000 unaffected controls. These included both existing datasets and two large-scale new datasets for replication studies. For the autosomal non- major histocompatibility complex (MHC) genome, they applied a partitioning approach to create regions of ±1 Mbp around the most statistically significant single nucleotide polymorphisms (SNP). The team designed the MS Chip using the Illumina iSelect platform, adding ~90K custom selected SNPs to the Illumina Exome Core content (~200K SNPs).
The team identified 233 associations with MS susceptibility that had genome-wide significance, including 32 loci on the major histocompatibility complex and one on the X chromosome. The latter might help explain why MS affects almost three times more women than men. Using gene expression and epigenomic data for T cells, monocytes, peripheral blood mononuclear cells, and prefrontal cortex tissue, the scientists found that MS risk loci are enriched in many types of immune cells and tissues, as well as in microglia, which are the immune cells of the brain, but not in other types of brain cells. Together with other functional studies into the effects of MS risk variants, they identified a list of 551 putative MS susceptibility genes with involvement in both innate and adaptive immune responses, many of which have roles in the development, maturation, and differentiation of B cells, T cells, natural killer cells, and myeloid cells.
The authors concluded that beyond the characterization of the molecular events that trigger MS, this map will also inform the development of primary prevention strategies because they can leverage this information to identify the subset of individuals who are at greatest risk of developing MS. Although insufficient by itself, an MS genetic risk score has a role to play in guiding the management of the population of individuals 'at risk' of MS (such as family members) when deployed in combination with other measures of risk and biomarkers that capture intermediate phenotypes along the trajectory from health to disease. The study was published on September 27, 2019, in the journal Science.
Related Links:
International Multiple Sclerosis Genetics Consortium
The role of the adaptive arm of the immune system, particularly its CD4+ T cell component, has become clearer, with multiple different T cell subsets being implicated. Although the T cell component plays an important role, functional and epigenomic annotation studies have begun to suggest that other elements of the immune system may be involved as well.
Scientists involved with the International Multiple Sclerosis Genetics Consortium (Boston, MA, USA) analyzed genotyping data from a total of more than 47,000 MS patients and more than 68,000 unaffected controls. These included both existing datasets and two large-scale new datasets for replication studies. For the autosomal non- major histocompatibility complex (MHC) genome, they applied a partitioning approach to create regions of ±1 Mbp around the most statistically significant single nucleotide polymorphisms (SNP). The team designed the MS Chip using the Illumina iSelect platform, adding ~90K custom selected SNPs to the Illumina Exome Core content (~200K SNPs).
The team identified 233 associations with MS susceptibility that had genome-wide significance, including 32 loci on the major histocompatibility complex and one on the X chromosome. The latter might help explain why MS affects almost three times more women than men. Using gene expression and epigenomic data for T cells, monocytes, peripheral blood mononuclear cells, and prefrontal cortex tissue, the scientists found that MS risk loci are enriched in many types of immune cells and tissues, as well as in microglia, which are the immune cells of the brain, but not in other types of brain cells. Together with other functional studies into the effects of MS risk variants, they identified a list of 551 putative MS susceptibility genes with involvement in both innate and adaptive immune responses, many of which have roles in the development, maturation, and differentiation of B cells, T cells, natural killer cells, and myeloid cells.
The authors concluded that beyond the characterization of the molecular events that trigger MS, this map will also inform the development of primary prevention strategies because they can leverage this information to identify the subset of individuals who are at greatest risk of developing MS. Although insufficient by itself, an MS genetic risk score has a role to play in guiding the management of the population of individuals 'at risk' of MS (such as family members) when deployed in combination with other measures of risk and biomarkers that capture intermediate phenotypes along the trajectory from health to disease. The study was published on September 27, 2019, in the journal Science.
Related Links:
International Multiple Sclerosis Genetics Consortium
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms